ICU

Business Context and Reporting Period

Company: Seastar Medical Holding Corp (ICU)

Reporting Period: Quarterly period ended June 30, 2025 (Form 10-Q)

Business Overview: Seastar is a commercial-stage healthcare company developing Selective Cytopheretic Devices (SCDs) to treat hyperinflammation. The company received FDA approval under a Humanitarian Device Exemption (HDE) for its pediatric SCD therapy, QUELIMMUNE, in February 2024, with commercial shipments beginning in July 2024. It is currently conducting a pivotal clinical trial for adult patients with acute kidney injury (AKI).

Key Financial Metrics

Liquidity: The company reported a net increase in cash of $4.48 million for the six months ended June 30, 2025, driven primarily by financing activities. However, management states that current cash is insufficient to fund operations for the next 12 months.

Material Changes vs. Prior Period

• Revenue Generation: The company recognized $631,000 in revenue for the six months ended June 30, 2025, compared to zero in the prior year period, following the commencement of commercial sales of QUELIMMUNE.
• Expense Reduction: Total operating expenses decreased by 28% ($2.4 million) year-over-year. Research and Development (R&D) expenses declined 14%, and General and Administrative (G&A) expenses declined 41%. Reductions were driven by decreased clinical trial costs, reduced consulting fees, and the rescission of unpaid employee and director bonuses.
• Non-Operating Items: The net loss improved significantly ($10.2 million reduction) largely due to the absence of a $6.1 million loss from the change in fair value of convertible notes recorded in the prior year period. In the current period, the company recorded a $32,000 gain on the change in fair value of liability-classified warrants.
• Debt Elimination: The company paid off all outstanding notes payable ($592,000) during the period, resulting in zero notes payable on the balance sheet as of June 30, 2025.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states that conditions raise substantial doubt about the company's ability to continue as a going concern. Management believes cash on hand is insufficient to fund operations, including clinical trials, for at least 12 months from the filing date.
• Capital Raising: The company is actively raising capital through equity offerings. Subsequent to the period end, the company completed a July 2025 public offering and an August 2025 registered direct offering. The company also has a $15 million Standby Equity Purchase Agreement (SEPA) and an At-The-Market (ATM) facility available.
• Nasdaq Compliance: On July 31, 2025, the company received notice of non-compliance with Nasdaq's $1.00 minimum bid price requirement. It has 180 days (until January 27, 2026) to regain compliance. The company previously regained compliance with the Minimum Stockholders' Equity requirement in July 2025 but remains under a mandatory panel monitor.
• Legal Proceedings: A putative securities class action lawsuit (Wells v. SeaStar Medical Holding Corporation) is pending, alleging misstatements regarding FDA approval timing and financial restatements. A related derivative action is stayed pending the resolution of the class action.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.3 million cash balance against the stated 12-month funding gap and the timing of future capital raises.
• Commercial Traction: Assess the sustainability of revenue growth from QUELIMMUNE, noting the company currently has only six customer sites.
• Dilution Risk: Review the terms of the July and August 2025 offerings and the outstanding warrant structure (over 18 million equity-classified warrants) to understand potential dilution.
• Nasdaq Status: Monitor the company's ability to maintain the $1.00 minimum bid price to avoid delisting.
• Legal Exposure: Track the status of the pending class action lawsuit and potential financial impact of a settlement or adverse judgment.